These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 26043084)

  • 1. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
    Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
    Yang L; Li N; Wang H; Jia X; Wang X; Luo J
    Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
    Ren L; Xiao L; Hu J
    J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
    Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
    J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
    Gong J; Xing C; Wang LY; Xie SS; Xiong WD
    J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
    Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
    Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
    J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
    Rao YM; Shi HR; Ji M; Chen CH
    J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.
    Feng C; Ma F; Hu C; Ma JA; Wang J; Zhang Y; Wu F; Hou T; Jiang S; Wang Y; Feng Y
    Cell Cycle; 2018; 17(4):448-458. PubMed ID: 29099271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
    Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
    Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
    Chen Q; Qin R; Fang Y; Li H
    Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
    Cai Y; An B; Yao D; Zhou H; Zhu J
    Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.